-+ 0.00%
-+ 0.00%
-+ 0.00%

Autolus presents 2026 net product revenue outlook of at least $150 million

PUBT·11/16/2026 12:22:13
Diffusion vocale
Autolus presents 2026 net product revenue outlook of at least $150 million
  • Autolus Therapeutics expects 2026 net product revenue of at least $150 million, the top of its prior guidance range.
  • Third-quarter Aucatzyl net product revenue rose 95% to $41.2 million.
  • Nine-month net product revenue increased 122% to $113.1 million.
  • Manufacturing success exceeds 90%, with no capacity limitations.
  • Phase 2 pediatric leukemia trial CATULUS is enrolling, with data expected at the end of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.